ALB and COVID-19: To corroborate our observation of increased levels of chronic hepatic pathology in COVID-19 patients, we decided to interrogate patient LFT results for all consecutive COVID-19-positive inpatients, for whom we could obtain admission LFT data (alanine transaminase (ALT) and albumin, alkaline phosphatase (ALP)), length of hospital stay and survival data (n = 276; average age 71 years; 109 (39%) female; 167 (61%) male).